NCT00669578View on ClinicalTrials.gov

CC-4047 in Treating Patients With Myelofibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

77

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

July 7, 2010

Study Completion Date

December 12, 2019

Conditions

Chronic Myeloproliferative DisordersSecondary Myelofibrosis

Interventions

DRUG

CC-4047

CC-4047: taken orally each day in a 28 day cycle.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER